Literature DB >> 19808839

A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.

Sotaro Miwa1, Atsushi Mizokami, Hiroyuki Konaka, Kouji Izumi, Takahiro Nohara, Mikio Namiki.   

Abstract

Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC). Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer. The patient in the present report had multiple bone metastases from RCC. Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks. Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment. The metastases have shown no progression for 20 months since starting the ZA treatment. We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808839     DOI: 10.1093/jjco/hyp122

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

Review 1.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

2.  Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.

Authors:  Matti Aapro; Fred Saad
Journal:  Ther Adv Urol       Date:  2012-04

3.  Complete Radiographic Response to Zoledronic Acid Therapy in a Patient With Bony Metastatic Urothelial Carcinoma: A Case Report.

Authors:  Matthew Kevin Riddle; Albert Craig Lockhart; Stephen M Sorscher
Journal:  World J Oncol       Date:  2010-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.